Tag: THERADIAG
Theradiag publishes its results for the first half of 2023 and shows significantly improved profitability – 09/18/2023 at 07:30
• Achievement of a strong operating margin of 12.5%, reflecting the significant improvement in industrial margins in Theradiag’s two businesses and the cessation of activities in the United States •…
Theradiag: 6.3 ME for the half-year turnover
AB Published on 07/17/2023 at 07:43 (Boursier.com) — Theradiag achieved revenue of 6.7 million euros compared to 6.3 million in…
Theradiag: 6.8% growth in half-year revenues – 07/17/2023 at 08:53
(AOF) – Theradiag published a turnover of 6.7 million euros in the first half, up 6.8%. “Growth accelerated slightly during the second quarter of 2023 thanks to good commercial performances…
Theradiag announces half-year 2023 revenue of €6.7 million, up 6.8% – 07/17/2023 at 07:30
• Strong growth compared to H1 2022 in the Theranostics business in H1 2023 at +18.0% driven by a very good export performance (outside the United States) • Slight acceleration…
Theradiag: 2022 net income of -487 K
By Arnaud Bives Published on 04/12/2023 at 08:02 (Boursier.com) — 2022, Theradiag generated revenue of €12.2 million compared to €11.1 million in…
Theradiag: Christian Policard is appointed chairman, Simon Davière managing director – 03/01/2023 at 18:02
(AOF) – The Theradiag Board of Directors has decided to appoint Christian Policard as Chairman to replace Pierre Morgon, who has resigned, and Simon Davière as Chief Executive Officer to…
THERADIAG: ANNOUNCEMENT OF THE FINAL RESULTS OF BIOSYNEX’S OPA ON THERADIAG SHARES – 02/01/2023 at 18:00
Croissy-Beaubourg, February 1, 2023, 6:00 p.m. CET – The Autorité des marchés financiers (AMF) published, on February 1, 2023, a notice of the final results of the reopened public takeover…
Theradiag: premium issue
Through Claude Leguilloux Published on 01/17/2023 at 09:54 Theradiag a announced the success of the takeover bid initiated by Biosynex, targeting the shares of…
Success of the takeover bid initiated by BIOSYNEX, targeting THERADIAG shares – 01/16/2023 at 6:00 p.m.
REOPENING OF THE OFFER FOR A MINIMUM DURATION OF 10 TRADING DAYS Croissy-Beaubourg, January 16, 2023, 6:00 p.m. CET – THERADIAG (ISIN: FR0004197747, Mnemonic: ALTER), a company specializing in in…
Theradiag: Unsurprising 2022 revenue
Read also (CercleFinance.com) – The Theradiag share rose slightly by 0.7% on Monday on the Paris Stock Exchange, investors being reassured by the unsurprising activity figures published in the morning…
Biosynex: successful takeover bid for Theradiag
(CercleFinance.com) – Euronext Paris informed the AMF that on January 12, the latest date set for the filing of orders submitted to the takeover bid initiated by Biosynex for Theradiag…
Theradiag: growth of nearly 10% in 2022 – 01/16/2023 at 08:00
(CercleFinance.com) – Theradiag posted revenue of €12.2 million for 2022, an increase of 9.7% in line with its business plan, with an increased share achieved abroad (55% compared to 52%…